secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-12-13T23:59:59+00:00
Accession:  0001193125-24-278717
Event type: other
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel prices $80M public offering of common stock and pre-funded warrants at $6.00/share
--------------------------------------------------------------------------------

- Offering: 10,000,001 common shares at $6.00/share plus pre-funded warrants for 3,333,333 shares at $5.99/warrant.
- Gross proceeds ~$80M; net proceeds ~$74.7M (or ~$86M if underwriters' 2M-share option is exercised).
- Proceeds to fund development, including BLA submission for CAN-2409 in prostate cancer, and general corporate purposes.
- Cash runway extended into Q1 2027; key data readouts expected in NSCLC/PDAC (Q1 2025) and recurrent glioblastoma (Q4 2025).
- Offering expected to close Dec 16, 2024; joint bookrunners: Citigroup, BofA Securities, Canaccord Genuity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312524278717/0001193125-24-278717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312524278717/d859956d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-278717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer